Subscribe To
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Overall sales value of pneumococcal vaccines market is estimated to cross a revenue of us$ 13.3 bn at a steady cagr of 4.1% by year 2033-end | data by future market insights, inc.
Surge in Demand for pneumococcal Vaccines Paves Way for Partnerships Amidst Government Bodies and Key M...
December 29, 2022, 8:30 pm
Merck's (mrk) pneumococcal vaccine gets fda nod for kids
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included i...
June 23, 2022, 10:03 am
Glaxosmithkline bolsters its vaccines r&d pipeline with us$3.3bn swoop for american drug developer
GlaxoSmithKline PLC (LSE:GSK) is to bolster its vaccine pipeline in a deal worth up to US$3.3bn. It is acquiring Affinivax Inc, which gives it access...
May 31, 2022, 2:35 am
Merck's (mrk) pneumococcal vaccine sbla faces fda delay
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included i...
April 4, 2022, 12:03 pm
Pfizer (pfe) gets eu nod for somatrogon & pneumococcal jab
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pne...
February 16, 2022, 1:09 pm
Pfizer (pfe) gets eu nod for somatrogon & pneumococcal jab
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pne...
February 16, 2022, 1:09 pm
Pfizer (pfe) gets eu nod for somatrogon & pneumococcal jab
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pne...
February 16, 2022, 1:09 pm